Umeå University's logo

umu.sePublikasjoner
Endre søk
Link to record
Permanent link

Direct link
Ärlestig, Lisbeth
Alternativa namn
Publikasjoner (10 av 37) Visa alla publikasjoner
Saevarsdottir, S., Stefansdottir, L., Sulem, P., Thorleifsson, G., Ferkingstad, E., Rutsdottir, G., . . . Saevarsdottir, S. (2022). Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset. Annals of the Rheumatic Diseases, 81(8), 1085-1095
Åpne denne publikasjonen i ny fane eller vindu >>Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset
Vise andre…
2022 (engelsk)Inngår i: Annals of the Rheumatic Diseases, ISSN 0003-4967, E-ISSN 1468-2060, Vol. 81, nr 8, s. 1085-1095Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objectives: To find causal genes for rheumatoid arthritis (RA) and its seropositive (RF and/or ACPA positive) and seronegative subsets.

Methods: We performed a genome-wide association study (GWAS) of 31 313 RA cases (68% seropositive) and ∼1 million controls from Northwestern Europe. We searched for causal genes outside the HLA-locus through effect on coding, mRNA expression in several tissues and/or levels of plasma proteins (SomaScan) and did network analysis (Qiagen).

Results: We found 25 sequence variants for RA overall, 33 for seropositive and 2 for seronegative RA, altogether 37 sequence variants at 34 non-HLA loci, of which 15 are novel. Genomic, transcriptomic and proteomic analysis of these yielded 25 causal genes in seropositive RA and additional two overall. Most encode proteins in the network of interferon-Alpha/beta and IL-12/23 that signal through the JAK/STAT-pathway. Highlighting those with largest effect on seropositive RA, a rare missense variant in STAT4 (rs140675301-A) that is independent of reported non-coding STAT4-variants, increases the risk of seropositive RA 2.27-fold (p=2.1×10-9), more than the rs2476601-A missense variant in PTPN22 (OR=1.59, p=1.3×10-160). STAT4 rs140675301-A replaces hydrophilic glutamic acid with hydrophobic valine (Glu128Val) in a conserved, surface-exposed loop. A stop-mutation (rs76428106-C) in FLT3 increases seropositive RA risk (OR=1.35, p=6.6×10-11). Independent missense variants in TYK2 (rs34536443-C, rs12720356-C, rs35018800-A, latter two novel) associate with decreased risk of seropositive RA (ORs=0.63-0.87, p=10-9-10-27) and decreased plasma levels of interferon-Alpha/beta receptor 1 that signals through TYK2/JAK1/STAT4.

Conclusion: Sequence variants pointing to causal genes in the JAK/STAT pathway have largest effect on seropositive RA, while associations with seronegative RA remain scarce.

sted, utgiver, år, opplag, sider
BMJ Publishing Group Ltd, 2022
Emneord
autoantibodies, polymorphism, genetic, rheumatoid arthritis
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-203215 (URN)10.1136/annrheumdis-2021-221754 (DOI)000788188500001 ()35470158 (PubMedID)2-s2.0-85130778612 (Scopus ID)
Forskningsfinansiär
VinnovaThe Research Council of NorwayPfizer ABEU, European Research CouncilThe Swedish Brain FoundationKnut and Alice Wallenberg FoundationSwedish Research Council, 2018-02803NordForsk, 90825The Research Council of Norway, 223273The Research Council of Norway, 229624Novo Nordisk, NNF15OC0016932
Tilgjengelig fra: 2023-01-18 Laget: 2023-01-18 Sist oppdatert: 2023-01-18bibliografisk kontrollert
Jönsson, E., Ljung, L., Norrman, E., Freyhult, E., Ärlestig, L., Dahlqvist, J. & Rantapää-Dahlqvist, S. (2022). Pulmonary fibrosis in relation to genetic loci in an inception cohort of patients with early rheumatoid arthritis from northern Sweden. Rheumatology, 61(3), 943-952
Åpne denne publikasjonen i ny fane eller vindu >>Pulmonary fibrosis in relation to genetic loci in an inception cohort of patients with early rheumatoid arthritis from northern Sweden
Vise andre…
2022 (engelsk)Inngår i: Rheumatology, ISSN 1462-0324, E-ISSN 1462-0332, Vol. 61, nr 3, s. 943-952Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

OBJECTIVES: Pulmonary manifestations in RA are common comorbidities. Interstitial lung disease (ILD), both idiopathic and in RA, has been associated with several genetic variants. We assessed pulmonary fibrosis (PF) in an inception cohort of RA patients in relation to genetic variants and disease-related factors.

METHODS: A total of 1466 early RA patients were consecutively included and followed prospectively from the index date until death or 31 December 2016. Clinical and laboratory data and treatment were continuously registered according to the Swedish Rheumatology Quality Register. DNA was available from 1184 patients and 571 151 genome-wide single-nucleotide polymorphisms (SNPs) were analysed. Thirteen identified genetic variants were extracted. At follow-up, the patients answered a questionnaire regarding disease progression and lung involvement that was validated by reviewing medical records and analysing radiological examinations.

RESULTS: The prevalence of PF was 5.6% and the annualized incidence rate was 5.0/1000 (95% CI 3.80, 6.54). Four SNPs were associated with PF in RA: rs35705950 [MUC5B; OR 2.5 (95% CI 1.5, 4.0), adjusted P-value = 0.00016, q-value = 0.0021]; rs111521887 [TOLLIP; OR 1.9 (95% CI 1.3, 2.8), adjusted P-value = 0.0014, q-value = 0.0092]; rs2609255 [FAM13A; OR 1.7 (95% CI 1.1, 2.5), adjusted P-value = 0.013, q-value = 0.055] and rs2736100 [TERT; OR 1.5 (95% CI 1.0, 2.2), adjusted P-value = 0.046, q-value = 0.15]. Older age and RF positivity were associated with increased risk, while MTX treatment was associated with a lower risk of PF.

CONCLUSIONS: Development of PF in an inception cohort of RA patients was associated with 4 of 12 ILD risk genes. RA-related factors except for age at diagnosis and RF positivity were of limited importance in PF development.

sted, utgiver, år, opplag, sider
British Society for Rheumatology, 2022
Emneord
pulmonary fibrosis, rheumatoid arthritis, rs111521887 (TOLLIP), rs2609255 (FAM13A), rs2736100 (TERT), rs35705950 (MUC5B)
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-193000 (URN)10.1093/rheumatology/keab441 (DOI)000755870900001 ()33993221 (PubMedID)2-s2.0-85125552923 (Scopus ID)
Tilgjengelig fra: 2022-03-14 Laget: 2022-03-14 Sist oppdatert: 2023-09-05bibliografisk kontrollert
Renman, E., Brink, M., Ärlestig, L., Rantapää-Dahlqvist, S. & Lejon, K. (2021). Dysregulated microRNA expression in rheumatoid arthritis families-a comparison between rheumatoid arthritis patients, their first-degree relatives, and healthy controls. Clinical Rheumatology, 40(6), 2387-2394
Åpne denne publikasjonen i ny fane eller vindu >>Dysregulated microRNA expression in rheumatoid arthritis families-a comparison between rheumatoid arthritis patients, their first-degree relatives, and healthy controls
Vise andre…
2021 (engelsk)Inngår i: Clinical Rheumatology, ISSN 0770-3198, E-ISSN 1434-9949, Vol. 40, nr 6, s. 2387-2394Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

OBJECTIVE: Recent studies have demonstrated an altered expression of certain microRNAs in patients with rheumatoid arthritis (RA) as well as their first-degree relatives (FDRs) compared to healthy controls (HCs), suggesting a role of microRNA in the progression of the disease. To corroborate this, a set of well-characterized RA families originating from northern Sweden were analyzed for differential expression of a selected set of microRNAs.

METHOD: MicroRNA was isolated from frozen peripheral blood cells obtained from 21 different families and included 26 RA patients, 22 FDRs, and 21 HCs. Expression of the selected microRNAs miR-22-3p, miR-26b-5p, miR-34a-3p, miR-103a-3p, miR-142-3p, miR-146a-5p, miR-155, miR-346, and miR-451a was determined by a two-step quantitative real-time polymerase chain reaction (qRT-PCR). Statistical analysis including clinical variables was applied.

RESULTS: Out of the nine selected microRNAs that previously have been linked to RA, we confirmed four after adjusting for age and gender, i.e., miR-22-3p (p = 0.020), miR-26b-5p (p = 0.018), miR-142-3p (p = 0.005), and miR-155 (p = 0.033). Moreover, a significant trend with an intermediate microRNA expression in FDR was observed for the same four microRNAs. In addition, analysis of the effect of corticosteroid use showed modulation of miR-103a-3p expression.

CONCLUSIONS: We confirm that microRNAs seem to be involved in the development of RA, and that the expression pattern in FDR is partly overlapping with RA patients. The contribution of single microRNAs in relation to the complex network including all microRNAs and other molecules is still to be revealed. Key Points • Expression levels of miR-22-3p, miR-26b-5p, miR-142-3p, and miR-155 were significantly altered in RA patients compared to those in controls. • In first-degree relatives, a significant trend with an intermediate microRNA expression in FDR was observed for the same four microRNAs.

sted, utgiver, år, opplag, sider
Springer, 2021
Emneord
Autoimmunity, MicroRNA family, Rheumatoid arthritis, Sweden
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-176964 (URN)10.1007/s10067-020-05502-9 (DOI)000591447600001 ()33210166 (PubMedID)2-s2.0-85096216498 (Scopus ID)
Forskningsfinansiär
Swedish Research Council, 201802551King Gustaf V Jubilee FundSwedish Rheumatism Association
Tilgjengelig fra: 2020-11-23 Laget: 2020-11-23 Sist oppdatert: 2023-03-24bibliografisk kontrollert
Ljung, L., Wiberg, K., Ärlestig, L. & Rantapää-Dahlqvist, S. (2019). Low-energy fractures in rheumatoid arthritis - associations with genes and clinical characteristics. Paper presented at Annual European Congress of Rheumatology (EULAR), Madrid, Spain, June 12-15, 2019. Annals of the Rheumatic Diseases, 78, 344-345
Åpne denne publikasjonen i ny fane eller vindu >>Low-energy fractures in rheumatoid arthritis - associations with genes and clinical characteristics
2019 (engelsk)Inngår i: Annals of the Rheumatic Diseases, ISSN 0003-4967, E-ISSN 1468-2060, Vol. 78, s. 344-345Artikkel i tidsskrift, Meeting abstract (Annet vitenskapelig) Published
Abstract [en]

Background: Patients with rheumatoid arthritis (RA) have increased risk of osteoporosis and low-energy fractures. Several genes associated with bone mineralization, osteoporosis or risk of fracture in the general population have been identified.

Objectives: To analyse the association between nine selected SNPs and the risk of low-energy fracture, taking clinical patient characteristics into account.

Methods: We identified a cohort of patients (n=896, 70% women, age at inclusion 60.0±14.8 years) with RA according to ACR criteria from the catchment area of the register of Umeå injury database, Umeå, Sweden, which enabled identification of low-energy fractures (n=254). The follow-up (mean 8.8±6.1 years, total 7928 person-years) started two years after RA diagnosis but not earlier than January 1, 1993 and ended at the first of December 31, 2011, death or the first low-energy fracture. Nine SNPs were analysed in all patients with available DNA-samples (n=667) using KASPTM genotyping assays (LGC genomics Ltd, Hoddesdon, UK): rs3801387 (WNT16), rs6666455 (SOAT), rs3736228 (LRP5), rs4796995 (FAM210A), rs4792909 (SOST), rs2062377 (TNFRSF11B/OPG), rs884205 (TNFRSF11A/RANK), rs9533090 (TNFSF11/RANKL), and rs1373004 (DKK1). Anti-CCP was analysed and clinical patient characteristics (duration of RA, ever smoking, disease activity the first two years after RA diagnosis, and joint erosions) were extracted from patient files. Associations between the risk of fracture and risk alleles in the cohort were evaluated using Kaplan-Meier curves (K-M) and Cox proportional hazards models: crude, adjusted for age and sex, and for clinical patient characteristics.

Results: The SNPs: rs1373004, rs4792909, and rs2062377 were associated with the risk of fracture in K-M analyses (Figure 1). For the other genes no significant associations were observed. Patients carrying the risk allele of rs1373004 (22.6% of the patients), or who were homozygous for the risk allele of SNP rs4792909 (38.6%), had a >50% higher risk of low-energy fracture compare to other patients, irrespectively of disease characteristics (Table 1). The association between rs2062377 and the risk of fracture was not independent of clinical patient characteristics (Table 1).

sted, utgiver, år, opplag, sider
BMJ Publishing Group Ltd, 2019
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-161726 (URN)10.1136/annrheumdis-2019-eular.4264 (DOI)000472207101052 ()
Konferanse
Annual European Congress of Rheumatology (EULAR), Madrid, Spain, June 12-15, 2019
Merknad

Supplement: 2

Meeting Abstract: THU0143

Tilgjengelig fra: 2019-07-26 Laget: 2019-07-26 Sist oppdatert: 2019-07-26bibliografisk kontrollert
Siljehult, F., Ärlestig, L., Eriksson, C. & Rantapää-Dahlqvist, S. (2018). Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 47(5), 345-350
Åpne denne publikasjonen i ny fane eller vindu >>Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis
2018 (engelsk)Inngår i: Scandinavian Journal of Rheumatology, ISSN 0300-9742, E-ISSN 1502-7732, Vol. 47, nr 5, s. 345-350Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective: The efficacy of anti-tumour necrosis factor-α (anti-TNF-α) treatment with infliximab (IFX) may be reduced by the development of anti-drug antibodies (ADAs). This study evaluated drug concentration and the presence of ADAs, relative to response, in rheumatoid arthritis (RA) patients treated with IFX.

Method: Ninety-four RA patients were consecutively included and assessed for disease activity at baseline, and after 14, and 30 or 52 weeks. Serum IFX concentration and ADAs were analysed using in-house enzyme-linked immunosorbent assays. ADA analysis was based on binding to TNF-α-coated plates, with the lower detection limit set at mean + 2 sd of controls.

Results: At 14 and 52 weeks, 74.5% of the patients had moderate to good response. Good responders had significantly higher IFX concentrations than moderate and poor responders at 52 weeks (6.6 ± 1.4 µg/mL vs 3.6 ± 1.3 µg/mL and 2.6 ± 1.6 µg/mL, respectively). An IFX concentration ≥4.66 µg/mL at 14 weeks yielded a moderate to good response at 30/52 weeks, with 91.3% specificity and 39.3% sensitivity. Eleven patients dropped out owing to lack of efficacy and eight owing to side effects; three with IFX concentration ≤ 0.5 µg/mL were ADA positive. At an IFX concentration ≤ 0.5 µg/mL, 43.8% and 30.1% at 14 and 52 weeks, respectively, were ADA positive. None of the good responders had ADAs.

Conclusion: One-quarter of patients had an IFX concentration ≤ 0.5 µg/mL but only 11.7% had ADAs. High IFX concentration was related to a good response, suggesting that the lack of response could be due to a lack of IFX, rather than to the presence of ADAs.

sted, utgiver, år, opplag, sider
Taylor & Francis Group, 2018
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-150975 (URN)10.1080/03009742.2018.1433232 (DOI)000443912500001 ()29701536 (PubMedID)2-s2.0-85046006206 (Scopus ID)
Tilgjengelig fra: 2018-08-21 Laget: 2018-08-21 Sist oppdatert: 2018-10-25bibliografisk kontrollert
Leonard, D., Svenungsson, E., Dahlqvist, J., Alexsson, A., Ärlestig, L., Taylor, K. E., . . . Rönnblom, L. (2018). Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. Annals of the Rheumatic Diseases, 77(7), 1063-1069
Åpne denne publikasjonen i ny fane eller vindu >>Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis
Vise andre…
2018 (engelsk)Inngår i: Annals of the Rheumatic Diseases, ISSN 0003-4967, E-ISSN 1468-2060, Vol. 77, nr 7, s. 1063-1069Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objectives Patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) have increased risk of cardiovascular disease (CVD). We investigated whether single nucleotide polymorphisms (SNPs) at autoimmunity risk loci were associated with CVD in SLE and RA.

Methods Patients with SLE (n=1045) were genotyped using the 200K Immunochip SNP array (Illumina). The allele frequency was compared between patients with and without different manifestations of CVD. Results were replicated in a second SLE cohort (n=1043) and in an RA cohort (n=824). We analysed publicly available genetic data from general population, performed electrophoretic mobility shift assays and measured cytokine levels and occurrence of antiphospholipid antibodies (aPLs).

Results We identified two new putative risk loci associated with increased risk for CVD in two SLE populations, which remained after adjustment for traditional CVD risk factors. An IL19 risk allele, rs17581834(T) was associated with stroke/myocardial infarction (MI) in SLE (OR 2.3 (1.5 to 3.4), P=8.5x10(-5)) and RA (OR 2.8 (1.4 to 5.6), P=3.8x10(-3)), meta-analysis (OR 2.5 (2.0 to 2.9), P=3.5x10(-7)), but not in population controls. The IL19 risk allele affected protein binding, and SLE patients with the risk allele had increased levels of plasma-IL10 (P=0.004) and aPL (P=0.01). An SRP54-AS1 risk allele, rs799454(G) was associated with stroke/transient ischaemic attack in SLE (OR 1.7 (1.3 to 2.2), P=2.5x10(-5)) but not in RA. The SRP54-AS1 risk allele is an expression quantitative trait locus for four genes.

Conclusions The IL19 risk allele was associated with stroke/MI in SLE and RA, but not in the general population, indicating that shared immune pathways may be involved in the CVD pathogenesis in inflammatory rheumatic diseases.

sted, utgiver, år, opplag, sider
BMJ Publishing Group Ltd, 2018
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-150481 (URN)10.1136/annrheumdis-2017-212614 (DOI)000438037000029 ()29514802 (PubMedID)2-s2.0-85051852146 (Scopus ID)
Tilgjengelig fra: 2018-08-13 Laget: 2018-08-13 Sist oppdatert: 2023-03-24bibliografisk kontrollert
Brink, M., Johansson, L., Nygren, E., Ärlestig, L., Hultdin, J. & Rantapää-Dahlqvist, S. (2018). Vitamin D in individuals before onset of rheumatoid arthritis: relation to vitamin D binding protein and its associated genetic variants. Scandinavian Journal of Rheumatology, 47, 23-24
Åpne denne publikasjonen i ny fane eller vindu >>Vitamin D in individuals before onset of rheumatoid arthritis: relation to vitamin D binding protein and its associated genetic variants
Vise andre…
2018 (engelsk)Inngår i: Scandinavian Journal of Rheumatology, ISSN 0300-9742, E-ISSN 1502-7732, Vol. 47, s. 23-24Artikkel i tidsskrift, Meeting abstract (Annet vitenskapelig) Published
sted, utgiver, år, opplag, sider
Taylor & Francis, 2018
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-151578 (URN)000442295400036 ()
Merknad

Supplement: 129

Meeting Abstract: PP19

Tilgjengelig fra: 2018-09-07 Laget: 2018-09-07 Sist oppdatert: 2020-06-18bibliografisk kontrollert
Johansson, L., Ärlestig, L., Kokkonen, H., Brink, M. & Rantapää-Dahlqvist, S. (2017). An increased concentration of receptor activator of nuclear factor kappa-B ligand pre-dates the onset of rheumatoid arthritis. Rheumatology, 56(12), 2190-2196
Åpne denne publikasjonen i ny fane eller vindu >>An increased concentration of receptor activator of nuclear factor kappa-B ligand pre-dates the onset of rheumatoid arthritis
Vise andre…
2017 (engelsk)Inngår i: Rheumatology, ISSN 1462-0324, E-ISSN 1462-0332, Vol. 56, nr 12, s. 2190-2196Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objectives: RANK ligand (RANKL) is involved in destruction and osteoporosis in RA. In this study, the relationships between RANKL and ACPA, anti-carbamylated protein antibodies (anti-CarP), cytokines and chemokines were analysed in individuals before the onset of RA symptoms, and their associations with radiological findings at disease onset were assessed.

Methods: This was a case-control study performed within the Medical Biobank of Northern Sweden that included 470 pre-symptomatic individuals [334 women and 136 men; mean (S.D.) age 52.3 (9.4) years] using blood samples donated before symptom onset (pre-dating time; 5.0 years) and 96 controls (60 women and 36 men). Plasma was analysed for RANKL (BioVendor, Karasek, Brno, Czech Republic), anti-CCP2 antibodies (Eurodiagnostics, Malmo, Sweden), anti-CarP antibodies (in-house ELISA), ACPA specificities (ISAC-platform, Phadia AB, Uppsala, Sweden) and cytokines/chemokines (Meso Scale Discovery methods, Rockville, MD, USA). Radiographs of hands and feet were graded using the Larsen score.

Results: The concentration of RANKL was higher in the pre-symptomatic individuals compared with controls; mean (S.E.M.): 0.50 (0.03) vs 0.22 (0.02) nmol/l (P < 0.001). The concentration increased gradually over time until symptom onset but appeared later than ACPA/RF/anti-CarP antibodies. Positivity for these antibodies yielded higher levels of RANKL compared with seronegativity (P < 0.001). RANKL concentrations were significantly associated with IL-6 and IL-10 concentrations. The combination of positivity for RANKL and anti-CarP antibodies resulted in a higher Larsen score at diagnosis beta = 6.18 (95% CI: 0.93, 11.43; P = 0.022).

Conclusion: RANKL concentrations were increased several years before symptom onset for RA, particularly in ACPA/RF/anti-CarP-positive individuals, all detectable earlier than RANKL. Positivity for RANKL and anti-CarP antibodies yielded the highest Larsen score at disease onset.

sted, utgiver, år, opplag, sider
Oxford University Press, 2017
Emneord
RANK ligand, ACPA, anti-CarP IgG, RA, pre-symptomatic individuals
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-163051 (URN)10.1093/rheumatology/kex339 (DOI)000416628500027 ()29029341 (PubMedID)2-s2.0-85038129437 (Scopus ID)
Tilgjengelig fra: 2019-09-11 Laget: 2019-09-11 Sist oppdatert: 2023-03-24bibliografisk kontrollert
Boman, A., Kokkonen, H., Ärlestig, L., Berglin, E. & Rantapää-Dahlqvist, S. (2017). Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis. Clinical Rheumatology, 35(5), 1005-1012
Åpne denne publikasjonen i ny fane eller vindu >>Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis
Vise andre…
2017 (engelsk)Inngår i: Clinical Rheumatology, ISSN 0770-3198, E-ISSN 1434-9949, Vol. 35, nr 5, s. 1005-1012Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The aim of this study was to analyze relationships between receptor activator of nuclear factor kappa-B (RANKL), sclerostin and their gene polymorphisms with radiological progression in patients with early rheumatoid arthritis (RA). Patients with early RA (n = 407, symptomatic <1 year) (ARA criteria) examined radiologically at inclusion and after 24 months were consecutively included. Disease activity score and C-reactive protein were regularly recorded. Sclerostin, RANKL, and anti-CCP2 antibodies were analyzed in plasma at baseline using ELISAs. Data on gene polymorphism for sclerostin and RANKL were extracted from Immunochip analysis. Sex- and age-matched controls (n = 71) were identified from the Medical Biobank of Northern Sweden. The concentration of RANKL was significantly higher in patients compared with controls, median (IQR) 0.56 (0.9) nmol/L and 0.20 (0.25) nmol/L (p < 0.001), and in anti-CCP2-positive patients compared with sero-negative individuals. Sclerostin was significantly increased in female patients 0.59 (0.47-0.65) ng/mL compared with female controls 0.49 (0.4-0.65) ng/mL (p < 0.02). RANKL concentration was related to the Larsen score at baseline (p < 0.01), after 24 months (p < 0.001), and to radiological progression at 24 months (p < 0.001). Positivity of RANKL and anti-CCP2 yielded significant risk for progression with negativity for both as reference. No single nucleotide polymorphism encoding TNFSF11 or SOST was associated with increased concentrations of the factors. The concentration of RANKL was related to the Larsen score at baseline, at 24 months, and radiological progression at 24 months particularly in anti-CCP2-positive patients, while the concentration of sclerostin was unrelated to radiological findings.

Emneord
Early rheumatoid arthritis, Radiological progression, Receptor activator of nuclear factor kappa-B ligand, Sclerostin, Single nucleotide polymorphism
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-133357 (URN)10.1007/s10067-017-3570-4 (DOI)000399879000004 ()28190118 (PubMedID)2-s2.0-85012180651 (Scopus ID)
Forskningsfinansiär
Swedish Research Council, K2013-52X-20307-07-3
Tilgjengelig fra: 2017-05-11 Laget: 2017-05-11 Sist oppdatert: 2023-03-23bibliografisk kontrollert
Jiang, X., Kallberg, H., Chen, Z., Ärlestig, L., Rantapää-Dahlqvist, S., Davila, S., . . . Alfredsson, L. (2016). An Immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis. Rheumatology, 55(1), 149-155
Åpne denne publikasjonen i ny fane eller vindu >>An Immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis
Vise andre…
2016 (engelsk)Inngår i: Rheumatology, ISSN 1462-0324, E-ISSN 1462-0332, Vol. 55, nr 1, s. 149-155Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective: To investigate the gene–environment interaction between smoking and single nucleotide polymorphisms (SNPs), using Immunochip material, on the risk of developing either of two serologically defined subsets of RA.

Methods: Interaction between smoking and 133 648 genetic markers from the Immunochip was examined for two RA subsets, defined by the presence or absence of ACPA. A total of 1590 ACPA-positive and 891 ACPA-negative cases were compared with 1856 controls in the Swedish Epidemiological Investigation of RA (EIRA) case–control study. Logistic regression models were used to determine the presence of interaction. The proportion attributable to interaction was calculated for each smoking–SNP pair. Replication was carried out in an independent dataset from northern Sweden. To further validate and extend the results, interaction analysis was also performed using genome-wide association studies data on EIRA individuals.

Results: In ACPA-positive RA, 102 SNPs interacted significantly with smoking, after Bonferroni correction. All 102 SNPs were located in the HLA region, mainly within the HLA class II region, 51 of which were replicated. No additional loci outside chromosome 6 were identified in the genome-wide association studies validation. After adjusting for HLA-DRB1 shared epitope, 15 smoking–SNP pairs remained significant for ACPA-positive RA, with 8 of these replicated (loci: BTNL2HLA-DRAHLA-DRB5HLA-DQA1HLA-DOB and TAP2). For ACPA-negative RA, no smoking–SNP pairs passed the threshold for significance.

Conclusion: Our study presents extended gene variation patterns involved in gene–smoking interaction in ACPA-positive, but not ACPA-negative, RA. Notably, variants in HLA-DRB1 and those in additional genes within the MHC class II region, but not in any other gene regions, showed interaction with smoking.

Emneord
rheumatoid arthritis, Immunochip, smoking, biological interaction, HLA-DRB1 shared epitope
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-129891 (URN)10.1093/rheumatology/kev285 (DOI)000369074800023 ()26272072 (PubMedID)2-s2.0-84960109796 (Scopus ID)
Tilgjengelig fra: 2017-01-12 Laget: 2017-01-10 Sist oppdatert: 2023-03-24bibliografisk kontrollert
Organisasjoner